Commentary

Podcast

Innovation Series: AI’s impact on managing ocular surface disease with Peter J. McDonnell, MD, and Laura M. Periman, MD

Artificial intelligence has the potential to improve ophthalmology practices by streamlining documentation, enhancing screening capabilities, and guiding more effective treatment decisions.

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss how artificial intelligence (AI) is transforming ophthalmology, especially in ocular surface disease. Periman highlights the potential of AI to streamline eye health screening and documentation, enabling ophthalmologists to focus on patients who require treatment. They emphasize how AI can enhance clinical efficiency, improve patient outcomes, and assist in making more precise treatment decisions. McDonnell adds that AI will allow ophthalmologists to have a much more productive and satisfying day in the clinic and operating room. Both believe AI will help advance the field and improve patient care globally.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
© 2025 MJH Life Sciences

All rights reserved.